MECHELEN, BELGIUM--(Marketwire - September 03, 2012) - Galapagos NV (EURONEXT BRUSSELS: GLPG)
today that its Board of Directors created 530,140 warrants under a new
plan for the benefit of employees, directors and independent consultants
Company and its subsidiaries.
On 3 September 2012, the Board of Directors of Galapagos approved the
Plan 2012" within the framework of the authorized capital. Under this
plan, 530,140 warrants were created, subject to acceptances.
The warrants created under Warrant Plan 2012 were offered on 3 September
mainly to employees of Galapagos and its subsidiaries and in secondary
its directors and consultants. The offer of warrants to directors has been
approved by the Extraordinary General Shareholders' Meeting held on
The warrants have an exercise term of eight years as of the date of the
and have an exercise price of EUR14.19 (the average closing price of the
Euronext Brussels during the thirty days preceding date of the offer).
warrants are not transferable and can in principle not be exercised prior
end of the third calendar year after the calendar year in which they
granted to the beneficiaries. Each warrant gives the right to subscribe
new Galapagos share. Should the warrants be exercised, Galapagos will
the listing of the resulting new shares on a regulated stock market.
warrants as such will not be listed on any stock market.
To date, Galapagos' total share capital amounts to EUR143,770,414.14;
number of securities conferring voting rights is 26,577,554, which is
total number of voting rights (the "denominator"), and all securities
voting rights and all voting rights are of the same category. The total
of rights (warrants) to subscribe to not yet issued securities conferring
rights is 3,696,502, which equals the total number of voting rights
result from the exercise of these warrants. Galapagos does not
convertible bonds or shares without voting rights outstanding.
Galapagos (EURONEXT BRUSSELS: GLPG) (PINKSHEETS: GLPYY) is a mid-size
biotechnology company specialized in the discovery and development of
molecule and antibody therapies with novel modes-of-action. The
progressing its JAK1 inhibitor GLPG0634, as well as one of the largest
in biotech, with four programs in development and over 30 discovery
The Galapagos Group has over 800 employees and operates facilities
countries, with global headquarters in Mechelen, Belgium. More
This release may contain forward-looking statements, including,
limitation, statements containing the words "believes,"
"expects," "intends," "plans," "seeks," "estimates," "may," "will,"
"stands to," and "continues," as well as similar expressions. Such
looking statements may involve known and unknown risks, uncertainties and
factors which might cause the actual results, financial condition,
or achievements of Galapagos, or industry results, to be materially
from any historic or future results, financial conditions,
achievements expressed or implied by such forward-looking statements.
these uncertainties, the reader is advised not to place any undue
such forward-looking statements. These forward-looking statements speak
of the date of publication of this document. Galapagos expressly
obligation to update any such forward-looking statements in this
reflect any change in its expectations with regard thereto or any
events, conditions or circumstances on which any such statement is based,
required by law or regulation.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Galapagos NV via Thomson Reuters ONE